Japanese pharmaceutical company Eisai recently announced the launch of Dayvigo (lemborexant), a new
続きを読む 2020-06-16ニュース
New medicine for insomnia! Eisai double-acting orexin receptor antagonist Dayvigo (lemborexant) is launched in the US!
The first c-Met inhibitor approved by the FDA to market
On May 6, the FDA approved the listing of Novartis Tabrecta (capmatinib) for the treatment of patien
続きを読む 2020-05-18
The cortisol synthesis inhibitor Isturia developed by Recordati has been approved by the European Union!
On January 16, 2020, the Italian pharmaceutical company Recordati recently announced that the Europe
続きを読む 2020-04-09
Fapilavir completes clinical research and shows good clinical efficacy
On March 17th, the State Council's joint prevention and control mechanism held a press conferenc
続きを読む 2020-03-22
Migraine relieved within 1 hour, FDA approves new oral medication
2020.02.27, Biohaven announced that the US FDA has approved the company's CGRP receptor inhibito
続きを読む 2020-03-01
Insomnia and schizophrenia innovative treatments approved
Dayvigo (lembroexant) developed by Eisai is an orexin receptor antagonist. Orexin is a neuropeptide
続きを読む 2020-02-03
First oral small molecule CGRP receptor inhibitor approved today for the treatment of migraine
Recently, the US FDA announced that it has approved the listing of the calcitonin gene-related pepti
続きを読む 2020-01-09
Novartis provides update on LUSTER Phase III studies in patients with uncontrolled GINA 4/5 asthma
Novartis recently announced topline results from its pivotal global Phase III LUSTER-11and LUSTER-22
続きを読む 2019-12-21
Roche T + A immunotherapy research achieves historic breakthrough
November 22, 2019, Roche announces data from positive studies of the IMbrave 150 phase III clinical
続きを読む 2019-12-12
Hansoh pharm's first sorts of new medicine "Flumatinib" will be approved for listing
Flumatinib is a tyrosine kinase inhibitor and it’s a second-generation TK inhibitor drug against Bcr
続きを読む 2019-11-19